| Literature DB >> 31881704 |
Md Obyedul Kalam Azad1, Wie Soo Kang1, Jung Dae Lim2, Cheol Ho Park1.
Abstract
Angelica gigas Nakai (<span class="Species">AGN) is a popular traditional herbal medicine which has been used to alleviate various human diseases in Korea since ancient times. However, the low bioaccessibility of the nutraceutical compounds of AGN results in a poor water solubility, thereby limiting bioavailability. In this regard, a ternary AGN-biopolymer-plasticizer composite (AGNC) was developed to enhance the bioaccessibility of nutraceutical compounds from extrudate AGN formulations manufactured by hot melt extrusion (HME). The AGNC was prepared with extrudate AGN (EAGN) using different hydroxypropyl methylcellulose (HPMC) biopolymers (5% w/w) viz.: hypromellose phthalate (HP), hypromellose (AN), and hypromellose (CN) along with acetic acid (AA) (0.1 M, 20% w/v) as a plasticizer. The non-extrudate fresh AGN (FAGN) powder was used as a control. The physicochemical properties of the extrudate formulations and control were characterized by differential scanning calorimetry (DSC) and Fourier-transform infrared spectroscopy (FTIR). DSC analysis showed a lower enthalpy (ΔH) (12.22 J/g) and lower glass transition temperature (Tg) (41 °C) in HP-AA-EAGN compared to the control. FTIR confirmed the physical crosslinking between AGN and biopolymer in the extrudate composite and demonstrated that some functional groups formed viz., -OH and -CH2. The obtained result also shows that the particle size was reduced by 341 nm, and solubility was increased by 65.5% in HP-AA-EAGN compared to the control (1499 nm, 29.4%, respectively). The bioaccessibility of the total phenolic content and the total flavonoids-including decursin (D) and decursinol angelate (DA)-were significantly higher in HP-AA-EAGN compared to the control. The 2,2-diphenyl-1 picryl hydrazyl (DPPH) free radical scavenging capacity and ferric reducing antioxidant power assay (FRAP) indicated that the HP-AA-EAGN formulation preserves a greater antioxidant profile than the other formulations. Finally, it is summarized that the addition of acidified HP biopolymer increased the bioaccessibility, functionality, and improved the physicochemical properties of nutraceutical compounds in the extrudate AGN formulation.Entities:
Keywords: Angelica gigas nakai; antioxidant capacity; bioaccessibility; biopolymer; hot melt extrusion; nanocomposite; phenolic compound; solubility
Year: 2019 PMID: 31881704 PMCID: PMC7169383 DOI: 10.3390/ph13010003
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Chemical structure of hydroxypropyl methylcellulose (HPMC) and their substitute groups.
Figure 2Schematic illustration of a hot melt extrusion process.
Grade and chemical attributes of the HPMC biopolymer.
| Polymer Grade | Chemical Name | Compositions | Generic Name | Molecular Weight | Gelling Temp. (°C) | Bulk Density (g/mL) | Viscosity (m Pa.s) at 20 (°C) | Functional Group |
|---|---|---|---|---|---|---|---|---|
| HP55 | Cellulose, 2-hydroxypropyl methyl ether phthalic acid ester | HPMC + Glacial acetic acid + Sodium cetate + Phthalic anhydride + Potassium chlorate | Hypro-mellose phthalate | 20,000–100,000 | 40–90 | 0.31–0.42 | 32–48 | Ether and phthalic acid ester |
| CN40H | Cellulose, 2-hydroxypropyl methyl ether | High Viscosity HPMC + HCl + H2O | Hypro-mellose | 10,000–1,000,000 | 40–90 | 0.30–0.52 | 4000 | Ether |
| AN6 | Cellulose, 2-hydroxypropyl methyl ether | Low Viscosity HPMC + HCl + H2O | Hypro-mellose | 10,000–1,000,000 | 40–90 | 0.30–0.52 | 6 | Ether |
Source: www.lotte-cellulose.com. Biopolymers used in this study was donated by the Lotte Chemical Co.
Composition of Angelica gigas Nakai (AGN)–biopolymer–plasticizer of the AGN–biopolymer–plasticizer composite (AGNC) formulation.
| Materials | Mixing Ratio ( | HME Condition | HME Temp. (°C) | Formulation |
|---|---|---|---|---|
| Fresh AGN powder | 100 | Non extrusion | -- | FAGN |
| AGN powder | 100 | Extrusion | 80/100/120/80 | EAGN |
| AGN + Acetic acid (AA) | 100 | Extrusion | 80/100/120/80 | AA-EAGN |
| AGN + AA + HP55 | 95-5 | Extrusion | 80/100/120/80 | HP-AA-EAGN |
| AGN + AA + CN40H | 95-5 | Extrusion | 80/100/120/80 | CN-AA-EAGN |
| AGN + AA+AN6 | 95-5 | Extrusion | 80/100/120/80 | AN-AA-EAGN |
Particle size distribution of the AGNC formulation.
| Formulations | Particle Size (nm) |
|---|---|
| FAGN | 1499 ± 5.4 a |
| EAGN | 478 ± 3.1 b |
| AA-EAGN | 448 ± 3.3 b |
| HP-AA-EAGN | 341 ± 3.4 c |
| CN-AA-EAGN | 354 ± 2.7 c |
| AN-AA-EAGN | 323 ± 2.1 c |
FAGN: fresh non-extrudate AGN; EAGN: extrudate AGN; AA-EAGN: acetic acid (0.1 M) mediated EAGN; HP/AN/CN-AA-EAGN: HPMC (5% w/w) mediated AA-EAGN. Values marked by different letters in each column were significantly different during the t-test (p < 0.05).
Figure 3Particle size distribution of the AGNC formulation. (A): FAGN; (B): EAGN; (C): AA-EAGN; (D): HP-AA-EAGN; (E): CN-AA-EAGN; (F): AN-AA-EAGN. HP/CN/AN-AA-EAGN: HPMC (5% w/w) mediated AA-EAGN.
Water solubility of the AGNC formulation.
| Formulations | WAI | WS (%) | SP |
|---|---|---|---|
| FAGN | 4.41 ± 0.50 a | 29.69 ± 0.94 d | 9.52 ± 1.31 a |
| EAGN | 3.27 ± 0.41 b | 42.54 ± 1.24 c | 5.31 ± 1.28 b |
| AA-EAGN | 3.75 ± 0.42 b | 51.35 ± 1.49 b | 5.65 ± 1.42 b |
| HP-AA-EAGN | 2.63 ± 0.93 c | 65.21 ± 1.28 a | 4.61 ± 0.88 c |
| CN-AA-EAGN | 2.54 ± 0.86 c | 59.34 ± 2.13 a | 4.15 ± 0.23 c |
| AN-AA-EAGN | 2.59 ± 0.43 c | 61.46 ± 1.91 a | 4.36 ± 0.71 c |
WAI: water absorption index; WS: water solubility; SP: swelling power. Values marked by different letters in each column are significantly different in the t-test (p < 0.05).
Figure 4Glass transition temperature (A) and glass transition energy (B) of the AGNC formulation.
Figure 5Fourier-transform infrared spectroscopy (FTIR) spectra of AGNC formulations.
Phenolic content and total flavonoid content of the AGNC formulation.
| AGNC Formulations | Total Phenol (mg/100 g) | Total Flavonoid (mg/100 g) |
|---|---|---|
| FAGN | 1421.0 ± 88.7 c | 119.5 ± 1.2 d |
| EAGN | 1649.2 ± 59.2 b | 138.1 ± 5.4 c |
| AA-EAGN | 1684.7 ± 48.3 b | 179.2 ± 1.4 b |
| HP-AA-EAGN | 2832 ± 62.6 a | 418.5 ± 22.2 a |
| CN-AA-EAGN | 2725 ± 46.24 a | 298 ± 24.14 a |
| AN-AA-EAGN | 2788 ± 55.94 a | 306 ± 13.74 a |
Values marked by different letters in each column are significantly different in the t-test (p < 0.05).
Figure 6The content of decursin (D) and decursinol angelate (DA) of the AGNC formulation. Values marked by different letters in each column are significantly different in the t-test (p < 0.05).
Figure 7The antioxidant capacity of the AGNC. DPPH (A) and FRAP (B). Values marked by different letters in each column are significantly different in the t-test (p < 0.05).